In this paper we describe the results of an extensive antibody screening effort that utilized our highthroughput, robotic, antibody-screening platform to screen through 1021 unique combinations of antibodies that target the SARS-CoV-2 nucleocapsid protein. Over the course of several months, as various SARS-CoV-2-related reagents became available, five screening rounds were conducted against a total of three different sources of SARS-CoV-2 nucleocapsid analyte. We primarily focused on the outcomes of three screening rounds (one each against different recombinant analytes and one against a diluted positive clinical positive pool) to highlight the differences in antibody pair rankings we obtained as a function of analyte variant.